

# Stephanie M Fullerton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2844458/publications.pdf>

Version: 2024-02-01

119  
papers

9,003  
citations

71102

41  
h-index

48315

88  
g-index

123  
all docs

123  
docs citations

123  
times ranked

13327  
citing authors

#	ARTICLE	IF	CITATIONS
1	Beyond inclusion: Enacting team equity in precision medicine research. PLoS ONE, 2022, 17, e0263750.	2.5	8
2	Family secrets: Experiences and outcomes of participating in direct-to-consumer genetic relative-finder services. American Journal of Human Genetics, 2022, 109, 486-497.	6.2	12
3	Stakeholder Perspectives on Returning Nonactionable Apolipoprotein L1 (APOL1) Genetic Results to African American Research Participants. Journal of Empirical Research on Human Research Ethics, 2022, 17, 4-14.	1.3	3
4	Polygenic risk, population structure and ongoing difficulties with race in human genetics. Philosophical Transactions of the Royal Society B: Biological Sciences, 2022, 377, 20200427.	4.0	10
5	Getting genetic ancestry right for science and society. Science, 2022, 376, 250-252.	12.6	93
6	Lessons learned and recommendations for data coordination in collaborative research: The CSER consortium experience. Human Genetics and Genomics Advances, 2022, , 100120.	1.7	2
7	Strategies of inclusion: The tradeoffs of pursuing "baked in" diversity through place-based recruitment. Social Science and Medicine, 2022, 306, 115132.	3.8	6
8	Relationship between genetic knowledge and familial communication of CRC risk and intent to communicate CRCP genetic information: insights from FamilyTalk eMERGE III. Translational Behavioral Medicine, 2021, 11, 563-572.	2.4	1
9	Ethical Considerations in the Use of Direct-to-Consumer Genetic Testing for Adopted Persons. Adoption Quarterly, 2021, 24, 89-100.	1.0	6
10	Four misconceptions about investigative genetic genealogy. Journal of Law and the Biosciences, 2021, 8, lsab001.	1.6	20
11	The FamilyTalk randomized controlled trial: patient-reported outcomes in clinical genetic sequencing for colorectal cancer. Cancer Causes and Control, 2021, 32, 483-492.	1.8	2
12	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature, 2021, 590, 290-299.	27.8	1,069
13	What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?. Patient Education and Counseling, 2021, 104, 726-731.	2.2	11
14	Patient and Family Preferences on Health System-Led Direct Contact for Cascade Screening. Journal of Personalized Medicine, 2021, 11, 538.	2.5	17
15	Neptune: an environment for the delivery of genomic medicine. Genetics in Medicine, 2021, 23, 1838-1846.	2.4	3
16	Generalizability of Polygenic Risk Scores for Breast Cancer Among Women With European, African, and Latinx Ancestry. JAMA Network Open, 2021, 4, e2119084.	5.9	31
17	Toward better governance of human genomic data. Nature Genetics, 2021, 53, 2-8.	21.4	31
18	At the Research-Clinical Interface. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1181-1189.	4.5	9

#	ARTICLE	IF	CITATIONS
19	Diversity and Inclusion in Unregulated mHealth Research: Addressing the Risks. <i>Journal of Law, Medicine and Ethics</i> , 2020, 48, 115-121.	0.9	10
20	Clinical Genetics Lacks Standard Definitions and Protocols for the Collection and Use of Diversity Measures. <i>American Journal of Human Genetics</i> , 2020, 107, 72-82.	6.2	52
21	Third-Party Genetic Interpretation Tools: A Mixed-Methods Study of Consumer Motivation and Behavior. <i>American Journal of Human Genetics</i> , 2019, 105, 122-131.	6.2	42
22	Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study. <i>Contemporary Clinical Trials</i> , 2019, 84, 105820.	1.8	6
23	Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. <i>American Journal of Human Genetics</i> , 2019, 105, 588-605.	6.2	99
24	Whole Genome Sequencing Identifies CRISPLD2 as a Lung Function Gene in Children With Asthma. <i>Chest</i> , 2019, 156, 1068-1079.	0.8	5
25	Ethics of inclusion: Cultivate trust in precision medicine. <i>Science</i> , 2019, 364, 941-942.	12.6	27
26	The Genomic Medicine Integrative Research Framework: A Conceptual Framework for Conducting Genomic Medicine Research. <i>American Journal of Human Genetics</i> , 2019, 104, 1088-1096.	6.2	35
27	“It would be so much easier” health system-led genetic risk notification” feasibility and acceptability of cascade screening in an integrated system. <i>Journal of Community Genetics</i> , 2019, 10, 461-470.	1.2	8
28	You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 526-530.	6.1	31
29	Practice Implications of Expanded Genetic Testing in Oncology. <i>Cancer Investigation</i> , 2019, 37, 39-45.	1.3	8
30	Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions. <i>American Journal of Nephrology</i> , 2019, 50, 303-311.	3.1	22
31	The Feelings About genomic Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. <i>Journal of Genetic Counseling</i> , 2019, 28, 477-490.	1.6	39
32	Hereditary cancer gene panel test reports: wide heterogeneity suggests need for standardization. <i>Genetics in Medicine</i> , 2018, 20, 1438-1445.	2.4	12
33	“Bridge to the Literature” Third-Party Genetic Interpretation Tools and the Views of Tool Developers. <i>Journal of Genetic Counseling</i> , 2018, 27, 770-781.	1.6	28
34	Informed Consent in Translational Genomics: Insufficient Without Trustworthy Governance. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 79-86.	0.9	18
35	Parents’ attitudes toward consent and data sharing in biobanks: A multisite experimental survey. <i>AJOB Empirical Bioethics</i> , 2018, 9, 128-142.	1.6	25
36	The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics. <i>Human Mutation</i> , 2018, 39, 1713-1720.	2.5	102

#	ARTICLE	IF	CITATIONS
37	The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations. <i>American Journal of Human Genetics</i> , 2018, 103, 319-327.	6.2	122
38	Cumulative Antidepressant Use and Risk of Dementia in a Prospective Cohort Study. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 1948-1955.	2.6	30
39	Celebrating STEM in Rural Communities: A Model for an Inclusive Science and Engineering Festival. <i>Journal of STEM Outreach</i> , 2018, 1, .	0.5	3
40	Public Attitudes toward Consent and Data Sharing in Biobank Research: A Large Multi-site Experimental Survey in the US. <i>American Journal of Human Genetics</i> , 2017, 100, 414-427.	6.2	172
41	Discordance in selected designee for return of genomic findings in the event of participant death and estate executor. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2017, 5, 172-176.	1.2	6
42	Clinical Genetic Testing for APOL1 : Are we There Yet?. <i>Seminars in Nephrology</i> , 2017, 37, 552-557.	1.6	29
43	Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2017, 5, 700-708.	1.2	1
44	Engaging Study Participants in Research Dissemination at a Center for Population Health and Health Disparities. <i>Progress in Community Health Partnerships: Research, Education, and Action</i> , 2016, 10, 569-576.	0.3	7
45	Genomics is failing on diversity. <i>Nature</i> , 2016, 538, 161-164.	27.8	1,346
46	Allocation of Resources to Communication of Research Result Summaries. <i>Journal of Empirical Research on Human Research Ethics</i> , 2016, 11, 364-369.	1.3	9
47	Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era. <i>BMC Medical Ethics</i> , 2016, 17, 39.	2.4	81
48	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , 2016, 98, 1051-1066.	6.2	137
49	Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities. <i>Health Affairs</i> , 2016, 35, 1367-1373.	5.2	67
50	Conducting a large, multi-site survey about patients'™ views on broad consent: challenges and solutions. <i>BMC Medical Research Methodology</i> , 2016, 16, 162.	3.1	9
51	No Panacea: Next-Gen Sequencing Will Not Mitigate Adoptees'™ Lack of Genetic Family Health History. <i>American Journal of Bioethics</i> , 2016, 16, 41-43.	0.9	5
52	Patient safety in genomic medicine: an exploratory study. <i>Genetics in Medicine</i> , 2016, 18, 1136-1142.	2.4	15
53	Rural Mexican-Americans'™ perceptions of family health history, genetics, and disease risk: implications for disparities-focused research dissemination. <i>Journal of Community Genetics</i> , 2016, 7, 91-96.	1.2	10
54	Patients' Choices for Return of Exome Sequencing Results to Relatives in the Event of Their Death. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 476-485.	0.9	19

#	ARTICLE	IF	CITATIONS
55	Awareness of Federal Regulatory Mechanisms Relevant to Community-Engaged Research. <i>Journal of Empirical Research on Human Research Ethics</i> , 2015, 10, 13-21.	1.3	4
56	Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network. <i>American Journal of Human Genetics</i> , 2015, 97, 512-520.	6.2	47
57	Prospective participant selection and ranking to maximize actionable pharmacogenetic variants and discovery in the eMERGE Network. <i>Genome Medicine</i> , 2015, 7, 67.	8.2	23
58	Looking for Trouble and Finding It. <i>American Journal of Bioethics</i> , 2015, 15, 15-17.	0.9	3
59	Broad Consent for Research With Biological Samples: Workshop Conclusions. <i>American Journal of Bioethics</i> , 2015, 15, 34-42.	0.9	221
60	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. <i>Genome Research</i> , 2015, 25, 305-315.	5.5	313
61	“Getting off the Bus Closer to Your Destination” Patients’ Views about Pharmacogenetic Testing. , 2015, 19, 21-27.		18
62	A review of the key issues associated with the commercialization of biobanks. <i>Journal of Law and the Biosciences</i> , 2014, 1, 94-110.	1.6	87
63	Returning Pleiotropic Results From Genetic Testing to Patients and Research Participants. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 795.	7.4	32
64	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. <i>American Journal of Human Genetics</i> , 2014, 94, 818-826.	6.2	342
65	Comparative effectiveness of next generation genomic sequencing for disease diagnosis: Design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. <i>Contemporary Clinical Trials</i> , 2014, 39, 1-8.	1.8	17
66	Refining the structure and content of clinical genomic reports. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 85-92.	1.6	37
67	Stakeholder engagement: a key component of integrating genomic information into electronic health records. <i>Genetics in Medicine</i> , 2013, 15, 792-801.	2.4	64
68	Forensic familial searching: scientific and social implications. <i>Nature Reviews Genetics</i> , 2013, 14, 445-445.	16.3	10
69	Return of incidental findings in genomic medicine: measuring what patients value—development of an instrument to measure preferences for information from next-generation testing (IMPRINT). <i>Genetics in Medicine</i> , 2013, 15, 873-881.	2.4	72
70	Using Genetically Informed, Randomized Prevention Trials to Test Etiological Hypotheses About Child and Adolescent Drug Use and Psychopathology. <i>American Journal of Public Health</i> , 2013, 103, S19-S24.	2.7	34
71	Informed Consent in Genome-Scale Research: What Do Prospective Participants Think?. <i>American Journal of Bioethics Primary Research</i> , 2012, 3, 3-11.	1.5	48
72	Familial Identification: Population Structure and Relationship Distinguishability. <i>PLoS Genetics</i> , 2012, 8, e1002469.	3.5	46

#	ARTICLE	IF	CITATIONS
73	What Are Our AIMS? Interdisciplinary Perspectives on the Use of Ancestry Estimation in Disease Research. <i>American Journal of Bioethics Primary Research</i> , 2012, 3, 87-97.	1.5	6
74	Research Guidelines in the Era of Large-scale Collaborations: An Analysis of Genome-wide Association Study Consortia. <i>American Journal of Epidemiology</i> , 2012, 175, 962-969.	3.4	23
75	Offering aggregate results to participants in genomic research: opportunities and challenges. <i>Genetics in Medicine</i> , 2012, 14, 490-496.	2.4	49
76	Finding a Place for Genomics in Health Disparities Research. <i>Public Health Genomics</i> , 2012, 15, 156-163.	1.0	25
77	From patients to partners: participant-centric initiatives in biomedical research. <i>Nature Reviews Genetics</i> , 2012, 13, 371-376.	16.3	250
78	Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. <i>Genetics in Medicine</i> , 2012, 14, 424-431.	2.4	94
79	Recommendations for ethical approaches to genotype-driven research recruitment. <i>Human Genetics</i> , 2012, 131, 1423-1431.	3.8	28
80	Beneficence, Clinical Urgency, and the Return of Individual Research Results to Relatives. <i>American Journal of Bioethics</i> , 2012, 12, 9-10.	0.9	10
81	Values in Translation: How Asking the Right Questions Can Move Translational Science Toward Greater Health Impact. <i>Clinical and Translational Science</i> , 2012, 5, 445-451.	3.1	22
82	Transdisciplinary approaches to understanding and eliminating ethnic health disparities: are we on the right track?. <i>Ethnicity and Disease</i> , 2012, 22, 504-8.	2.3	3
83	Secondary uses and the governance of de-identified data: Lessons from the human genome diversity panel. <i>BMC Medical Ethics</i> , 2011, 12, 16.	2.4	23
84	Ethical and practical challenges of sharing data from genome-wide association studies: The eMERGE Consortium experience. <i>Genome Research</i> , 2011, 21, 1001-1007.	5.5	68
85	dbGaP Data Access Requests: A Call for Greater Transparency. <i>Science Translational Medicine</i> , 2011, 3, 113cm34.	12.4	17
86	Response—The Risks and Benefits of Re-Consent. <i>Science</i> , 2011, 332, 306-306.	12.6	5
87	Research Practice and Participant Preferences: The Growing Gulf. <i>Science</i> , 2011, 331, 287-288.	12.6	86
88	Parent Perspectives on Pediatric Genetic Research and Implications for Genotype-Driven Research Recruitment. <i>Journal of Empirical Research on Human Research Ethics</i> , 2011, 6, 41-52.	1.3	49
89	Inferring Genetic Ancestry: Opportunities, Challenges, and Implications. <i>American Journal of Human Genetics</i> , 2010, 86, 661-673.	6.2	214
90	Population description and its role in the interpretation of genetic association. <i>Human Genetics</i> , 2010, 127, 563-572.	3.8	21

#	ARTICLE	IF	CITATIONS
91	Glad You Asked: Participants' Opinions of Re-Consent for DbGap Data Submission. <i>Journal of Empirical Research on Human Research Ethics</i> , 2010, 5, 9-16.	1.3	116
92	SPANX Gene Variation in Fertile and Infertile Males. <i>Systems Biology in Reproductive Medicine</i> , 2010, 56, 18-26.	2.1	15
93	Meeting the Governance Challenges of Next-Generation Biorepository Research. <i>Science Translational Medicine</i> , 2010, 2, 15cm3.	12.4	69
94	Genomic research and wide data sharing: Views of prospective participants. <i>Genetics in Medicine</i> , 2010, 12, 486-495.	2.4	172
95	Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. <i>Genetics in Medicine</i> , 2010, 12, 616-620.	2.4	55
96	Ethical and Practical Guidelines for Reporting Genetic Research Results to Study Participants. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 574-580.	5.1	328
97	Race-Based Medicine and Justice as Recognition: Exploring the Phenomenon of BiDiL. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2009, 18, 57-67.	0.8	17
98	Race and ancestry in biomedical research: exploring the challenges. <i>Genome Medicine</i> , 2009, 1, 8.	8.2	106
99	Genes, Environment, and Cancer Disparities. , 2009, , 49-82.		2
100	Sharing Data and Experience: Using the Clinical and Translational Science Award (CTSA) "Moral Community" to Improve Research Ethics Consultation. <i>American Journal of Bioethics</i> , 2008, 8, 37-39.	0.9	8
101	Strategies and Stakeholders: Minority Recruitment in Cancer Genetics Research. <i>Public Health Genomics</i> , 2008, 11, 241-249.	1.0	40
102	Racialized Genetics and the Study of Complex Diseases: The Thrifty Genotype Revisited. <i>Perspectives in Biology and Medicine</i> , 2007, 50, 203-227.	0.5	77
103	Relationships with Test-Tubes: Where's the Reciprocity?. <i>American Journal of Bioethics</i> , 2006, 6, 36-38.	0.9	19
104	Genomics, epidemiology, and common complex diseases: let's not throw out the baby with the bathwater! Authors' response. <i>International Journal of Epidemiology</i> , 2006, 35, 1364-1365.	1.9	0
105	Dissecting complex disease: the quest for the Philosopher's Stone?. <i>International Journal of Epidemiology</i> , 2006, 35, 562-571.	1.9	97
106	On stones, wands, and promises. <i>International Journal of Epidemiology</i> , 2006, 35, 593-596.	1.9	26
107	Racing around, getting nowhere. <i>Evolutionary Anthropology</i> , 2005, 14, 165-169.	3.4	56
108	Population Genetics of CAPN10 and GPR35: Implications for the Evolution of Type 2 Diabetes Variants. <i>American Journal of Human Genetics</i> , 2005, 76, 548-560.	6.2	69

#	ARTICLE	IF	CITATIONS
109	The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster. <i>Human Genetics</i> , 2004, 115, 36-56.	3.8	41
110	Geographic and Haplotype Structure of Candidate Type 2 Diabetes-Susceptibility Variants at the Calpain-10 Locus. <i>American Journal of Human Genetics</i> , 2002, 70, 1096-1106.	6.2	117
111	Sequence polymorphism at the human apolipoprotein AII gene (APOA2): unexpected deficit of variation in an African-American sample. <i>Human Genetics</i> , 2002, 111, 75-87.	3.8	28
112	Local Rates of Recombination Are Positively Correlated with GC Content in the Human Genome. <i>Molecular Biology and Evolution</i> , 2001, 18, 1139-1142.	8.9	277
113	Polymorphism and Divergence in the $\beta$ -Globin Replication Origin Initiation Region. <i>Molecular Biology and Evolution</i> , 2000, 17, 179-188.	8.9	20
114	Sequence Diversity and Large-Scale Typing of SNPs in the Human Apolipoprotein E Gene. <i>Genome Research</i> , 2000, 10, 1532-1545.	5.5	156
115	Phenogenetic Drift and the Evolution of Genotype-Phenotype Relationships. <i>Theoretical Population Biology</i> , 2000, 57, 187-195.	1.1	160
116	Apolipoprotein E Variation at the Sequence Haplotype Level: Implications for the Origin and Maintenance of a Major Human Polymorphism. <i>American Journal of Human Genetics</i> , 2000, 67, 881-900.	6.2	377
117	Molecular and population genetic analysis of allelic sequence diversity at the human beta-globin locus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 1805-1809.	7.1	105
118	HpaI, HindIII, and BamHI polymorphisms of the human $\beta$ -globin gene can be detected by a single polymerase chain reaction amplification product. <i>American Journal of Hematology</i> , 1994, 47, 256-256.	4.1	10
119	A Proposed Approach for Implementing Genomics-Based Screening Programs for Healthy Adults. <i>NAM Perspectives</i> , 0, , .	2.9	30